Do analysts prefer CRMD or MENS?

CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 75.64%. Given CorMedix's stronger consensus rating and higher probable upside, equities analysts plainly believe CorMedix is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CRMD or MENS?

CorMedix has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $311.71M 2.15 $163.05M $2.13 4.01 Jyong Biotech N/A N/A N/A N/A N/A

Does the media refer more to CRMD or MENS?

In the previous week, CorMedix and CorMedix both had 1 articles in the media. CorMedix's average media sentiment score of 0.94 equaled Jyong Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AVTE or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, AVTE or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Jyong Biotech N/A N/A N/A N/A N/A

Is AVTE or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Jyong Biotech N/A N/A N/A

Do analysts prefer CLYM or MENS?

Climb Bio currently has a consensus price target of $20.30, indicating a potential upside of 86.07%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Climb Bio is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.08 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CLYM or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Jyong Biotech N/A N/A N/A N/A N/A

Is CLYM or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Jyong Biotech N/A N/A N/A

Does the media refer more to CLYM or MENS?

In the previous week, Climb Bio and Climb Bio both had 1 articles in the media. Jyong Biotech's average media sentiment score of 0.94 beat Climb Bio's score of 0.93 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MENS or TLRY?

Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 121.58%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tilray Brands 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, MENS or TLRY?

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A N/A N/A N/A Tilray Brands $821.31M 0.74 -$2.19B -$13.65 N/A

Does the media favor MENS or TLRY?

In the previous week, Tilray Brands had 9 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Tilray Brands and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.94 beat Tilray Brands' score of 0.40 indicating that Jyong Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tilray Brands 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACRS or MENS?

Aclaris Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 144.16%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ACRS or MENS?

Jyong Biotech has lower revenue, but higher earnings than Aclaris Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclaris Therapeutics $7.83M 84.01 -$64.92M -$0.56 N/A Jyong Biotech N/A N/A N/A N/A N/A

Does the media refer more to ACRS or MENS?

In the previous week, Aclaris Therapeutics had 12 more articles in the media than Jyong Biotech. MarketBeat recorded 13 mentions for Aclaris Therapeutics and 1 mentions for Jyong Biotech. Aclaris Therapeutics' average media sentiment score of 1.17 beat Jyong Biotech's score of 0.94 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jyong Biotech (MENS) Competitors

$2.10 +0.01 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.24%)

As of 04:10 PM Eastern

Compare

MENS vs. CRMD, AVTE, CLYM, TLRY, and ACRS

Should you buy Jyong Biotech stock or one of its competitors? MarketBeat compares Jyong Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jyong Biotech include CorMedix (CRMD), Aerovate Therapeutics (AVTE), Climb Bio (CLYM), Tilray Brands (TLRY), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Jyong Biotech compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, CorMedix and CorMedix both had 1 articles in the media. CorMedix's average media sentiment score of 0.94 equaled Jyong Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.15	$163.05M	$2.13	4.01
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 75.64%. Given CorMedix's stronger consensus rating and higher probable upside, equities analysts plainly believe CorMedix is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CorMedix has a net margin of 45.25% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Jyong Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Jyong Biotech	N/A	N/A	N/A

34.2% of CorMedix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CorMedix beats Jyong Biotech on 9 of the 9 factors compared between the two stocks.

How does Jyong Biotech compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

In the previous week, Jyong Biotech had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Aerovate Therapeutics. Jyong Biotech's average media sentiment score of 0.94 beat Aerovate Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Jyong Biotech	Positive

Jyong Biotech's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Jyong Biotech	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jyong Biotech beats Aerovate Therapeutics on 5 of the 5 factors compared between the two stocks.

How does Jyong Biotech compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

69.8% of Climb Bio shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Climb Bio currently has a consensus price target of $20.30, indicating a potential upside of 86.07%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Climb Bio is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Jyong Biotech	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

In the previous week, Climb Bio and Climb Bio both had 1 articles in the media. Jyong Biotech's average media sentiment score of 0.94 beat Climb Bio's score of 0.93 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats Jyong Biotech on 6 of the 9 factors compared between the two stocks.

How does Jyong Biotech compare to Tilray Brands?

Jyong Biotech (NASDAQ:MENS) and Tilray Brands (NASDAQ:TLRY) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Jyong Biotech has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Jyong Biotech's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Tilray Brands	-156.51%	-3.31%	-2.42%

Jyong Biotech has higher earnings, but lower revenue than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	N/A	N/A	N/A
Tilray Brands	$821.31M	0.74	-$2.19B	-$13.65	N/A

9.4% of Tilray Brands shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tilray Brands had 9 more articles in the media than Jyong Biotech. MarketBeat recorded 10 mentions for Tilray Brands and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.94 beat Tilray Brands' score of 0.40 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 121.58%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Tilray Brands beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Jyong Biotech compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Jyong Biotech has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Jyong Biotech's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Jyong Biotech	N/A	N/A	N/A

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jyong Biotech has lower revenue, but higher earnings than Aclaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	84.01	-$64.92M	-$0.56	N/A
Jyong Biotech	N/A	N/A	N/A	N/A	N/A

In the previous week, Aclaris Therapeutics had 12 more articles in the media than Jyong Biotech. MarketBeat recorded 13 mentions for Aclaris Therapeutics and 1 mentions for Jyong Biotech. Aclaris Therapeutics' average media sentiment score of 1.17 beat Jyong Biotech's score of 0.94 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jyong Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 144.16%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aclaris Therapeutics beats Jyong Biotech on 9 of the 12 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MENS vs. The Competition

Export

Metric	Jyong Biotech	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$158.90M	$992.36M	$4.34B	$12.44B
Dividend Yield	N/A	4.84%	7.93%	5.33%
P/E Ratio	N/A	1.01	18.44	22.64
Price / Sales	N/A	122.18	182.31	115.68
Price / Cash	N/A	20.06	53.68	55.53
Price / Book	N/A	8.12	30.95	6.72
Net Income	N/A	-$3.91M	$109.80M	$337.03M
7 Day Performance	-6.67%	-1.73%	-0.42%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	15.64%	33.98%

Jyong Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MENS Jyong Biotech	N/A	$2.10 +0.5%	N/A	N/A	$158.90M	N/A	N/A	31
CRMD CorMedix	3.4961 of 5 stars	$8.24 +3.3%	$15.00 +82.0%	-34.7%	$646.43M	$311.71M	3.87	30
AVTE Aerovate Therapeutics	N/A	$22.21 -5.3%	N/A	+146.5%	$643.76M	N/A	N/A	20	High Trading Volume
CLYM Climb Bio	3.1952 of 5 stars	$11.18 +1.6%	$20.30 +81.6%	+709.3%	$640.17M	N/A	N/A	9
TLRY Tilray Brands	3.664 of 5 stars	$5.38 +1.7%	$11.50 +113.8%	+27.8%	$627.04M	$821.31M	N/A	2,842

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jyong Biotech (MENS) Competitors

MENS vs. CRMD, AVTE, CLYM, TLRY, and ACRS

How does Jyong Biotech compare to CorMedix?

Summary

How does Jyong Biotech compare to Aerovate Therapeutics?

Summary

How does Jyong Biotech compare to Climb Bio?

Summary

How does Jyong Biotech compare to Tilray Brands?

Summary

How does Jyong Biotech compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jyong Biotech (MENS) Competitors

MENS vs. CRMD, AVTE, CLYM, TLRY, and ACRS

How does Jyong Biotech compare to CorMedix?

Does the media refer more to CRMD or MENS?

Which has preferable valuation and earnings, CRMD or MENS?

Do analysts prefer CRMD or MENS?

Is CRMD or MENS more profitable?

Do institutionals and insiders believe in CRMD or MENS?

Summary

How does Jyong Biotech compare to Aerovate Therapeutics?

Does the media refer more to AVTE or MENS?

Is AVTE or MENS more profitable?

Which has better valuation and earnings, AVTE or MENS?

Do analysts prefer AVTE or MENS?

Summary

How does Jyong Biotech compare to Climb Bio?

Do insiders & institutionals believe in CLYM or MENS?

Do analysts prefer CLYM or MENS?

Is CLYM or MENS more profitable?

Which has higher earnings and valuation, CLYM or MENS?

Does the media refer more to CLYM or MENS?

Summary

How does Jyong Biotech compare to Tilray Brands?

Is MENS or TLRY more profitable?

Which has stronger valuation and earnings, MENS or TLRY?

Do insiders & institutionals believe in MENS or TLRY?

Does the media favor MENS or TLRY?

Do analysts rate MENS or TLRY?

Summary

How does Jyong Biotech compare to Aclaris Therapeutics?

Is ACRS or MENS more profitable?

Do insiders and institutionals believe in ACRS or MENS?

Which has preferable valuation and earnings, ACRS or MENS?

Does the media refer more to ACRS or MENS?

Do analysts rate ACRS or MENS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools